Last reviewed · How we verify
HRS-1893 Tablets
HRS-1893 is an investigational small molecule with unknown mechanism of action in Phase 3 development.
At a glance
| Generic name | HRS-1893 Tablets |
|---|---|
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding the specific molecular mechanism of HRS-1893. As a Phase 3 candidate from Shandong Suncadia Medicine Co., Ltd., the drug is in late-stage clinical development, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases or literature.
Approved indications
Common side effects
Key clinical trials
- A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants (PHASE1)
- A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects (PHASE1)
- A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction (PHASE2)
- Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function (PHASE1)
- A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy (PHASE2)
- A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy (PHASE3)
- A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy (PHASE2)
- A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |